NCX4016: a novel antithrombotic agent.
Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents. Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential. Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation--all activities not exerted by aspirin. In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive. Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment.
Gresele
P
P
Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Via Enrico dal Pozzo, 06126 Perugia, Italy. grespa@unipg.it
Momi
S
S
Mezzasoma
A M
AM
D000818:Animals; D001241:Aspirin / Q000031:analogs & derivatives / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D009000:Monocytes / Q000187:drug effects; D009569:Nitric Oxide / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011655:Pulmonary Embolism / Q000188:drug therapy; D011817:Rabbits; D051381:Rats
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; C102148:nitroaspirin; D001241:Aspirin